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Abstract
Primary cutaneous anaplastic large cell lymphoma (PCALCL) is a rare 
subset of CD30+ lymphoproliferative disorder, characterized by the presence 
of large anaplastic cells, which express CD30, CD2, CD3, CD4, and CD5. 
A 62 year-old male patient presented to our Institute with a history of a fast-
growing and pinkish-brown asymptomatic cutaneous nodule. His medical past 
history was positive for a malignant melanoma (MM) of the abdomen (0.7 mm 
Breslow thickness; pT1a). Histologically the lesion showed a diffuse infiltrate 
consisting in cohesive sheets of large cells with anaplastic morphology with a 
kidney-shaped nucleus, also known as hallmark cells. Immunohistochemical 
studies revealed a CD30 expression, and a positivity to perforin and anaplastic 
lymphoma kinase (ALK). The laboratory and instrumental investigations were all 
normal and a final diagnosis of PCALCL was made. The patient showed a good 
response to radiotherapy. Usually PCALCL shares with systemic anaplastic 
large cell lymphoma (ALCL) the presence of neoplastic CD30+ large T cells, but 
lack ALK translocations and protein expression. However, the detection of ALK 
expression in PCALCL should be considered highly suspicious of a cutaneous 
manifestation of an underlying systemic disease (not detected in our patient). 
We recommend to exclude a systemic involvement in this kind of disease, with 
a strict follow-up, especially in patients with double malignancies. 
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(Figure 3A), and a strong positivity to perforin and anaplastic 
lymphoma kinase (ALK) were also detected (Figure 3B).
According to the histopathological and clinical features a 
diagnosis of cutaneous anaplastic large cells lymphoma (CALCL) 
CD30 positive and ALK positive was made. Consequently, an osteo-
medullary biopsy (OMB) was performed, showing a hematopoietic 
bone-marrow cellularity of 25% (CD20 + B lymphocytes 5% and 
CD3+ T lymphocytes 7% with interstitial random distribution) in 
the absence of localization of lymphoma. The total body CT and the 
laboratory investigations were also negative.
Case Presentation
A62 year-old Caucasian male patient presented to our Institute 
with a 15 days history of a fast-growing and pinkish-brown 
asymptomatic nodule (2cm x 3cm) in the left pectoral area. The lesion 
was not painful, not malodorous, firm on palpation and produced a 
serous secretion. The surrounding skin was erythematous (Figure 1).
His familiar history was negative for malignancies and other 
diseases; while his medical past history was positive for a malignant 
melanoma (MM) of the abdomen, 0.7 mm Breslow thickness, not 
ulcerated, (pT1a N0 M0; Stage IA), which was removed 5 years before.
For the nodular lesion, the patients’ general practitioner 
prescribed an oral antibiotic therapy (amoxicillin + clavunalate 1gr 
daily for 5 days), without any improvement.
In this regard, according to the appearance of the cutaneous lesion 
and to the personal medical history, a wide excision was performed.
Histologically the lesion showed a diffuse infiltrate consisting 
in cohesive sheets of cells with anaplastic morphology and variable 
sizes (from small to large). The neoplastic elements showed round, 
oval and/or irregularly-shaped nuclei with prominent eosinophilic 
nucleoli. The most distinctive appearance was the presence of large 
cells with a kidney-shaped nucleus, also known as hallmark cells. 
The cytoplasm was typically abundant, eccentrically placed, with 
prominent nucleoli (Figure 2A; 2B). Immunohistochemical studies 
revealed a CD30 expression in the majority of the neoplastic cells 
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Figure 1: Asymptomatic nodule (2cm x3cm) in the left pectoral area. The 
lesion was not painful, not malodorous and firm on palpation. The surrounding 
skin was erythematous.
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According to the absence of systemic involvement, a final 
diagnosis of primary of cutaneous anaplastic large cells lymphoma 
(PCALCL), ALK+ was made. Our patient was staged as T2a N0 M0, 
according to the International Society for Cutaneous Lymphoma 
(ISCL) and Cutaneous Lymphoma Task Force of the European 
Organization of Research and Treatment of Cancer (EORTC) [1].
Two weeks after the primary surgical excision of the cutaneous 
lesion, the patient returned at our Department with a further nodular 
lesion in correspondence of the surgical scar. Therefore, a second 
wide excision was performed and the histological examination 
confirmed the same diagnosis. Hence, the patient started a course of 
local radiotherapy with 40 Gy (2 Gy in 20 daily fractions).
Currently, after a follow-up of 1 year, the patient is disease free 
and he performs periodical clinical and instrumental controls.
Discussion
Primary cutaneous T-cell lymphoma (PCTCL) is a wide group 
of different non-Hodgkin lymphomas, characterized by clonal 
expansion of skin-homing malignant T lymphocytes [1,2]. Primary 
cutaneous CD30+ disorders accounts for 30% of cutaneous T-cell 
lymphomas and are currently classified in primary cutaneous 
anaplastic large cell lymphoma (PCALCL), lymphomatoid papulosis 
(LyP) and borderline subset [1-3]. Diagnosis of PCALCL is possible 
when the following three criteria are fulfilled: (a) >75% presence of 
CD30+ anaplastic large cells in skin biopsy, (b) negative clinical past 
history for other cutaneous lymphomas, (c) absence of extracutaneous 
localization [2,3].
PCALCL is histologically characterized by the presence of 
large anaplastic cells, which express CD30, CD2, CD3, CD4, and 
CD5 (T-helper phenotype); although, to date, in literature, several 
histopathological variants (basing on the type of cell that predominate 
in the infiltrate and on the size of the malignant lymphocytes) are also 
reported [4-6].
Our patient fulfilled all the diagnostic criteria and therefore was 
correctly diagnosed as PCALCL. Besides, according to the literature, 
PCALCL can be also classified as T-(CD3+), B-(CD20+) or null-
(CD3-, CD20-) cell immunophenotype [4,7,8]. Our case was CD3- 
and CD20- and was classified as a null-cell type. Finally, a cytotoxic 
T-cell phenotype (CD8+) PCALCL has been also rarely reported in 
literature [9].
Clinically, PCALCL is often a solitary, asymptomatic, reddish 
to lilaceous nodule, with erythematous peripheral borders. It is 
frequently localized on the trunk and extremities and affects mostly 
male and elderly patients, with a median age of 60 years, as reported 
in our case.
The etiopathogenesis of the disease is currently unknown; most 
likely the clonal expansion of CD30+ cells is influenced by host 
immune response [1,4]. In this regard and in the general spectrum of 
anaplastic large cell lymphomas, previous reports found also a close 
relationship among pro-inflammatory mediators such as HMBG-
1, MMP-9, PAR-2 and IL-8 chemokine in the development of the 
lymphoma cell invasion and metastasization [4,10,11]. However, to 
date, the causes of the onset of the disease are still to elucidate.
ALK is frequently observed in systemic ALCL, mostly in 
childhood or adolescence, but only rarely in primary cutaneous 
cases [4]. Translocations involving ALK gene detected by 
immunohistochemistry as positive staining with antibodies against 
ALK is observed in 50 to 80% of systemic ALCL cases, but is rarely 
detected in PCALCL. Besides, PCALCL remains confined to the skin, 
virtually never disseminates beyond local lymph nodes, and shows an 
excellent prognosis after surgical resection without systemic therapy 
[12]. However, in this regard, recently published recommendations 
state that immunohistochemical detection of ALK expression should 
be considered highly suspicious of a cutaneous manifestation of an 
underlying systemic ALCL [12,13].
For this reason, after the histological diagnosis, we decided 
to perform an osteo-medullar-biopsy (OMB) and a total-body 
CT. Besides, although up to 25% of patients with PCALCL show a 
regression of the lesion [8], in our case the nodule reappeared 15 days 
after the primary surgical wide excision, showing a locally aggressive 
course.
It is widely reported in literature an association between 
cutaneous melanoma and non-Hodgkin’s lymphoma, as well as an 
increased risk of non-Hodgkin’s lymphoma following cutaneous 
melanoma and vice versa [14]. This intriguing possible association is 
of interest in terms of understanding their etiology, which is likely 
to be multifactorial [14]. In this regard, for both the tumors, UV 
exposure, chronic immunosuppression and genetic predisposition 
were assessed as possible precipitating factors [14,15]. Further 
researches are necessary to elucidate the role of different common 
aetiological factors responsible for this association.
Regarding the therapy, PCACL is a chemosensitive and 
radiosensitive lymph proliferative disorder; treatments include 
surgical excision, CHOP (cyclophosphamide, doxorubicin, 
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Figure 2a: Infiltrate of cohesive sheets of cells with anaplastic morphology, 
with variable sizes (X10, Hematoxilin and Eosin).
Figure 2b: Alarge cell population with kidney-shaped nucleus, with abundant 
cytoplasm, eccentrically placed. (X 40, Hematoxilin and Eosin).
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Figure 3a: Diffuse strong CD30 positivity (X 40).
Figure 3b: Diffuse ALK positivity(X 40).
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vincristine, prednisone) or local radiotherapy (as well as a combination 
of these treatments) [16]. Up to date, the optimal dose for treatment 
of CALCL remains an open issue, although complete responses with 
dosages between 34 and 44 Gy have proved to be highly effective [16]. 
Our patient performed two local surgical excisions, followed by only 
radiotherapy and currently is disease free.
According to our experience, we recommend for PCACL (ALK+) 
baseline MOB and total body CT, in order to exclude a systemic 
involvement and a strict follow-up, especially in patients with double 
malignancies, as reported in our case.
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